SER-109 is the lead Seres Ecobiotic® microbiome therapeutic in clinical testing for the treatment of recurrent Clostridium difficile infection (CDI). SER-109 was developed utilizing the Seres Microbiome Therapeutics™ platform that provides insight into the ecologies of disease and then identifies microbial compositions that can catalyze a shift to health. CDI is a rapidly growing problem associated with antibiotic use. Approximately 85,000 to 110,000 CDI patients in the U.S. are expected to have more than one recurrence.

    [td_text_with_title custom_title=”Latest post”]

    Seres up 185% to 52 dollars

    InRater hotstock Seres Therapeutical, with a recent BTD status from 12 th of June,  hit the Nasdaq in full force today with a 100% increase in marketcap.  This is a stock we will be monitoring for possible investment, but being outside of the US we could not, alas, participate in the IPO. We made a […]


    Seres Therapeutics sets terms for $100 million IPO

    Seres Therapeutics, which is developing therapies that replace beneficial bacteria to treat infections, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Seres Therapeutics would command a fully […]


    Seres Therapeutics Receives FDA Breakthrough Therapy Designation

    Seres Therapeutics, Inc., a leading microbiome therapeutics platform company, today announced that SER-109 (Firmacute Eubacterial Spores, Purified Suspension, Encapsulated), its lead product candidate under investigation for the prevention of recurrent Clostridium difficile infection (CDI) in adults, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). Breakthrough therapy designation is intended to expedite […]